Monitor for patent grant status in Japan and any subsequent clinical development milestones for 3-MMC/dyskinesia program. No near-term revenue catalyst — stock movement likely driven by broader sector sentiment or pipeline updates.
Price Chart
Executive Summary
Clearmind Medicine announced the publication of a patent application in Japan covering 3-MMC-based treatment for dyskinesia, including combinations with PEA. This is a routine IP milestone for a clinical-stage biotech with no revenue or near-term catalyst — the patent has not yet been granted, and no clinical or financial data was disclosed.
Key Facts
- Patent application published in Japan covers 3-MMC for treating dyskinesia, including combinations with PEA.
- Application is part of ongoing collaboration with NeuroThera Labs Inc. (TSXV: NTLX).
- Clearmind's IP portfolio consists of 19 patent families including 32 granted patents.
- No revenue, clinical data, or financial figures disclosed in the filing.
Financial Impact
No financial impact disclosed — patent publication is an early-stage IP event with no immediate revenue or cost implications.
Risk Factors
- Patent may not be granted or may issue in a less favorable form.
- No clinical data yet for 3-MMC in dyskinesia — early-stage pipeline risk.
- Clearmind has no approved products and limited cash runway visibility from this filing.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-107727 |
| Document: ea030805601ex99-1.htm | 0001213900-26-107727 |
| Document: 0001213900-26-107727-index-headers.html | 0001213900-26-107727 |
| Document: 0001213900-26-107727-index.html | 0001213900-26-107727 |
| Document: 0001213900-26-107727.txt | 0001213900-26-107727 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.74%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.25%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.25%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.16%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.16%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.45%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.31%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers